A more efficient reduction in FGF23 levels may indeed contribute to the lower risk of cardiovascular mortality in kidney transplant recipients who develop hypophosphatemia within 12 months, since FGF23 has been implicated in cardiovascular disease [79,80,81] and a higher risk of cardiovascular mortality in kidney transplant recipients [76,82]. This evidence concerns the gene FGF23 and hypophosphatemia.